Agios Pharm

NASDAQ AGIO

Data sourced from

and

Daily

Download Data

Agios Pharm Price to Book Ratio (P/B) on June 03, 2024: 3.34

Agios Pharm Price to Book Ratio (P/B) is 3.34 on June 03, 2024, a 140.73% change year over year. The price to book ratio compares the market price per share of a company's stock to its book value per share. It is calculated by dividing the market capitalization by the shareholders' equity minus treasury stock, divided by the number of outstanding shares. This ratio provides insights into how the market values a company relative to its book value. A ratio above 1 indicates the market values the company more than its book value, suggesting positive market sentiment.

Agios Pharm 52-week high Price to Book Ratio (P/B) is 3.34 on June 03, 2024, which is 0.00% below the current Price to Book Ratio (P/B).
Agios Pharm 52-week low Price to Book Ratio (P/B) is 1.25 on October 27, 2023, which is -62.57% below the current Price to Book Ratio (P/B).
Agios Pharm average Price to Book Ratio (P/B) for the last 52 weeks is 1.69.

NASDAQ: AGIO

Agios Pharm

CEO	Dr. Bruce D. Car DACVP, Ph.D.
IPO Date	July 24, 2013
Location	United States
Headquarters	88 Sidney Street, Cambridge, MA, United States, 02139-4169
Employees	383
Sector	Healthcare
Industry	Biotechnology

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key trends